Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 14/20 | 0.54 |
| ▸ | CHRNA4 | P43681 | 14/20 | 0.54 |
| ▸ | CHRNB4 | P30926 | 12/20 | 0.54 |
| ▸ | CHRNA3 | P32297 | 10/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23463665 | 0.86 | CHRNB2 (0.41) | CHRNB2CHRNA4CHRNB4CHRNA3ALDH1A1 | |
| SCHEMBL247201 | 0.80 | CHRNB2 (0.54) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL26004047 | 0.78 | CHRNB2 (0.55) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL23771190 | 0.78 | CHRNB2 (0.76) | CHRNB2CHRNA4CHRNB4CHRNA3ALDH1A1 | |
| SCHEMBL24230520 | 0.75 | CHRNB2 (0.43) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL23771192 | 0.75 | TSHR (0.50) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL16846175 | 0.74 | — | — | |
| SCHEMBL19546492 | 0.73 | ALDH1A1 (0.41) | CHRNB2CHRNA4CHRNB4CHRNA3ALDH1A1 | |
| SCHEMBL27432649 | 0.73 | ALDH1A1 (0.41) | CHRNB2CHRNA4CHRNB4ALDH1A1 | |
| SCHEMBL2736112 | 0.73 | CHRNB2 (0.47) | CHRNB2CHRNA4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210047319-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-02-18 | — | — | US | disclosed |
| US-10781204-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2020-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210047319-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | CHRNB2 3189/4885CHRNA4 4028/4885CHRNB4 3883/4885 |
| US-10781204-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK1, JAK2 | CHRNB2 3099/4885CHRNA4 4038/4885CHRNB4 3958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.